LEP and breast cancer: To this end, AD-MSCs may promote EMT in cells of breast cancer (BC) through several pathways, particularly acting through PI3K/AKT signaling and p38 MAP kinase [81,82], or alternatively by overexpressing leptin, as identified by AD-MSCs coming from patients affected by obesity [83].